Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are consistent with the provided label excerpts (indication and several adverse events), but multiple statements overreach beyond label wording (e.g., 'main/common' and bowel-stool specifics) and at least one monitoring claim is not supported by the provided text.
Category Scores
Accurate Statements
Sancuso (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
Indications and Usage section 1 (prevention of nausea and vomiting in moderately/highly emetogenic chemotherapy regimens of up to 5 consecutive days).
Common side effects reported for granisetron medicines include constipation.
Adverse Reactions 6.2 (constipation listed under gastrointestinal adverse events for other formulations of granisetron).
Common side effects reported for granisetron medicines include headache.
Adverse Reactions 6.2 (headache listed under central nervous system adverse events for other formulations of granisetron).
Some people report dizziness with granisetron products.
Adverse Reactions 6.2 (dizziness listed under central nervous system adverse events for other formulations of granisetron).
With 5-HT3 antagonists, clinicians watch for anaphylaxis/severe hypersensitivity and trouble breathing (shortness of breath), and urticaria.
Adverse Reactions 6.2 (hypersensitivity reactions sometimes severe including anaphylaxis, shortness of breath; urticaria).
With patches, severe reactions or generalized skin reactions require removal of the patch.
Warnings and Precautions 5.2 (If severe reactions or generalized skin reaction occur, the patch must be removed).
Sancuso is a selective 5-HT3 receptor antagonist.
Clinical Pharmacology 12.1 (granisetron described as a selective 5-HT3 receptor antagonist).
Unsupported Statements
Sancuso is commonly used in patients receiving chemotherapy.
Indication wording supports use in specified chemotherapy regimens but does not state 'commonly used.' (Indications and Usage section 1).
Common side effects reported for granisetron medicines include fatigue.
Label excerpt lists 'asthenia' rather than the term 'fatigue.' (Adverse Reactions 6.2).
Constipation is one of the main side effects associated with granisetron-based anti-nausea therapy.
Label excerpt lists constipation but does not characterize it as 'main' or provide ranking/frequency language. (Adverse Reactions 6.2).
Patients may notice fewer bowel movements with granisetron-based anti-nausea therapy.
Label excerpt does not mention decreased bowel movement frequency. (Adverse Reactions 6.2).
Patients may notice harder stools with granisetron-based anti-nausea therapy.
Label excerpt does not mention stool hardness/consistency. (Adverse Reactions 6.2).
Patients may experience abdominal discomfort with granisetron-based anti-nausea therapy.
Label excerpt lists 'abdominal pain' but does not state 'abdominal discomfort.' (Adverse Reactions 6.2).
With 5-HT3 antagonists, clinicians watch for severe or persistent constipation with significant abdominal pain or inability to pass stool/gas.
Provided label excerpt discusses masking ileus/gastric distention, but does not include the specific monitoring statement about constipation with inability to pass stool/gas. (Warnings and Precautions 5.1, provided excerpts).
With patches, users should monitor for skin-related reactions at the application site, such as redness, irritation, or rash.
Provided label excerpt describes that application site reactions were generally mild and that severe/generalized skin reactions require removal, but does not list 'redness/irritation' monitoring examples in the provided text. (Warnings and Precautions 5.2; also placement guidance in Dosage and Administration 2 is not monitoring).
Sancuso is in the same class as other 5-HT3 blockers (like ondansetron).
Label excerpt confirms class mechanism (selective 5-HT3 antagonist) but does not explicitly compare to ondansetron or state 'like ondansetron.' (Clinical Pharmacology 12.1).
Constipation and headache are side effects people often associate with the 5-HT3 blocker class.
Label excerpt does not include any statement about what people 'often associate' with the class. (Adverse Reactions 6.2).
The patch formulation changes how the drug is delivered and can affect how side effects feel day-to-day.
Provided excerpts do not support claims about day-to-day subjective side-effect changes due to patch formulation. (Provided sections: Indications, Adverse Reactions, Warnings, Dosage/Admin application, Clinical Pharmacology).
With 5-HT3 antagonists, a severe reaction requires prompt medical attention.
Provided label excerpt supports severe hypersensitivity reactions exist and patch removal for severe/generalized skin reactions, but does not explicitly state 'prompt medical attention.' (Adverse Reactions 6.2; Warnings and Precautions 5.2).
If a severe skin reaction occurs, the patch should be removed and medical advice obtained.
Provided label excerpt states patch must be removed for severe/generalized skin reactions, but does not explicitly state obtaining 'medical advice.' (Warnings and Precautions 5.2).
Contradictions
Important Omissions
Dose/usage regimen details for Sancuso (e.g., schedule/dosing duration) were not provided in the AI claims.
Importance:
Moderate
Specific contraindications, boxed warnings, and other safety precautions were not addressed by the AI claims set. (These sections were not provided in the excerpts, so this is a coverage/omission evaluation rather than a label contradiction.)
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Main issues are phrasing/overreach beyond provided label wording (e.g., 'main/common', bowel-stool specifics) and one unsupported monitoring claim; the provided excerpts still support general risks like constipation, hypersensitivity, and patch removal for severe/generalized skin reactions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements extend beyond the label excerpt wording (ranking/frequency, bowel-stool specifics, and specific monitoring phrasing) and some safety actions are not explicitly stated as 'prompt medical attention'/'medical advice obtained.'
Suggested Improvement
Replace overreaching language with label-supported wording (e.g., describe constipation/headache as adverse events without ranking; avoid bowel-movement frequency or stool-hardness claims; align monitoring language to masking ileus/gastric distention and severe/generalized skin reaction removal language exactly as shown in the provided sections).